secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVVITY, INC. (RVTY)
CIK:        0000031791
Form:       8-K/A
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001193125-21-320153
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLegend FY2020 audited: revenue $241.9M, net income $90.6M
------------------------------------------------------------

- BioLegend net sales $241.9M, gross profit $169.7M, operating income $109.6M, net income $90.2M.
- Total assets $465.9M at Dec 31, 2020; cash $134.4M, short-term investments $90.0M.
- Pro forma combined financials for PerkinElmer and BioLegend for FY2020 and H1 2021 filed.
- Acquisition completed Sept 17, 2021 via merger of wholly owned subsidiaries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/31791/000119312521320153/0001193125-21-320153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/31791/000119312521320153/d169075d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-320153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer